Sera were evaluated in both untreated (C57BL/6) and AhR agonist VAF347-treated (+VAF347) non-diabetic (ND) and STZ-diabetic (DB) mice to quantify average blood glucose levels through a glycated hemoglobin A1c (HbA1c) analysis at week 6 and 29 after diabetes was confirmed (Table 1). This evidence concerns the gene AHR and diabetes mellitus.